Directory
>
Justin To
Justin To
CEO, Skeletal Dysplasias (QED Therapeutics) | BridgeBio
San Francisco, California, United States
Justin To
Summary
Justin To is an accomplished CEO at QED Therapeutics, a subsidiary of BridgeBio, specializing in the development of innovative therapies for skeletal dysplasias. With a robust background in biochemistry and molecular biology, Justin has effectively transitioned from consulting at McKinsey to leading major operations in the biotech sector. His leadership experience spans several high-level roles at BridgeBio, where he has driven strategic initiatives in gene therapy and business development. Justin's educational foundation from Harvard University in Chemistry complements his extensive expertise in biotechnology. He is known for his adaptability in fast-paced environments and his commitment to advancing medical science. Outside of his professional pursuits, Justin is passionate about fostering innovation in healthcare and mentoring emerging leaders in the industry.
Justin To
Work Experience
CEO, Skeletal Dysplasias (QED Therapeutics) at
BridgeBio
January 2024 - Present
Chief Operating Officer, Skeletal Dysplasias and Gene Therapy at
BridgeBio
September 2022 - January 2024
Chief Operating Officer, Gene Therapy at
BridgeBio
September 2020 - November 2022
Vice President of Business Development and Operations, Gene Therapy at
BridgeBio
March 2018 - September 2020
Associate Director of Portfolio Management at
BridgeBio
August 2017 - March 2018
Product Commercialization at
Flatiron Health
June 2016 - July 2017
Consultant at
McKinsey & Company
August 2014 - May 2016
Justin To
Education
Harvard University, A.B
Frequently Asked Questions about Justin To
What is Justin To email address?
Justin To's primary email address is ***@bridgebio.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Justin To work for?
Justin To is a CEO, Skeletal Dysplasias (QED Therapeutics) at BridgeBio, a company specializing in Commercial physical research.
Where Justin To graduated from?
Justin To holds a degree in Chemistry from Harvard University.
How can I directly contact Justin To?
To contact Justin To directly, you can use the email address ***@bridgebio.com. Complete contact information is available upon registration with Muraena.
Who is Justin To?
Justin To is an accomplished CEO at QED Therapeutics, a subsidiary of BridgeBio, specializing in the development of innovative therapies for skeletal dysplasias. With a robust background in biochemistry and molecular biology, Justin has effectively transitioned from consulting at McKinsey to leading major operations in the biotech sector. His leadership experience spans several high-level roles at BridgeBio, where he has driven strategic initiatives in gene therapy and business development. Justin's educational foundation from Harvard University in Chemistry complements his extensive expertise in biotechnology. He is known for his adaptability in fast-paced environments and his commitment to advancing medical science. Outside of his professional pursuits, Justin is passionate about fostering innovation in healthcare and mentoring emerging leaders in the industry.
Justin`s contact details
***@bridgebio.com
Colleagues
Senior Vice President - Head of Market Access - BridgeBio
Vice President, Head of Program Management
VP Law, Associate General Counsel
SVP of Strategy and Operations
Senior Vice President Marketing
Vice President, Talent
Vice President, Computational Genomics
Vice President Supply Chain Management